Stock NLSP NLS PHARMACEUTICS LTD.
Add to a list
To use this feature you must be a member
Log inSign up

NLS Pharmaceutics Ltd. Stock

Equities

NLSP

CH0523961370

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-24 pm EDT 		5-day change 1st Jan Change
0.125 USD -3.99% Intraday chart for NLS Pharmaceutics Ltd. -6.02% -78.81%
Apr. 08 Nls Pharmaceutics Ltd. Announces Resignation of Anthony S. Walsh as A Member of the Board of Directors CI
Apr. 03 NLS Pharmaceutics Ltd. announced that it has received $1.75 million in funding CI

Financials (USD)

Sales 2021 - Sales 2022 - Capitalization 42.83M
Net income 2021 -11M Net income 2022 -16M EV / Sales 2021 -
Net cash position 2021 5.43M Net cash position 2022 8.95M EV / Sales 2022 -
P/E ratio 2021
-1.11 x
P/E ratio 2022
-1.54 x
Employees -
Yield 2021 *
-
Yield 2022
-
Free-Float 63.27%
More Fundamentals * Assessed data

Chart NLS Pharmaceutics Ltd.

Dynamic Chart

Latest news about NLS Pharmaceutics Ltd.

Nls Pharmaceutics Ltd. Announces Resignation of Anthony S. Walsh as A Member of the Board of Directors CI
NLS Pharmaceutics Ltd. announced that it has received $1.75 million in funding CI
NLS Pharmaceutics Ltd. announced that it expects to receive $1.75 million in funding CI
NLS Pharmaceutics Files Plan to Regain Nasdaq Listing Compliance MT
NLS Pharmaceutics AG Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Sector Update: Health Care Stocks Rise in Late Afternoon Trading MT
Sector Update: Health Care Stocks Rise in Afternoon Trading MT
Top Midday Gainers MT
NLS Pharmaceutics Signs Option Agreement to Acquire Rights to Aexon Labs' Assets; Shares Rise MT
NLS Pharmaceutics Announces Exploration of Strategic Alternatives to Maximize Shareholder Value CI
Maxim Downgrades NLS Pharmaceutics to Hold From Buy MT
Top Premarket Gainers MT
NLS Pharmaceutics Ltd. cancelled the transaction announced on August 19, 2022 CI
Sector Update: Health Care Stocks Steady Pre-Bell Monday MT
NLS Pharmaceutics' Mazindol ER Trial to Move to Phase 3 MT
More news

Analyst Recommendations on NLS Pharmaceutics Ltd.

Maxim Downgrades NLS Pharmaceutics to Hold From Buy MT
Maxim Upgrades NLS Pharmaceutics to Buy From Hold, Price Target is $4 MT
Maxim Downgrades NLS Pharmaceutics to Hold From Buy MT
Laidlaw Starts NLS Pharmaceutics at Buy With $6 Price Target MT
Alliance Global Initiates Coverage on NLS Pharmaceutics With Buy Rating MT
More recommendations

Press releases NLS Pharmaceutics Ltd.

NLS Pharmaceutics : Various Claims Against the Company - Form 6-K PU
NLS Pharmaceutics : SECOND ADDENDUM TO THE - Form 6-K PU
NLS Pharmaceutics to Participate in the BIO-EUROPE Springtime Partnering Event AQ
NLS Pharmaceutics Submits Plan to Regain Listing Compliance with Nasdaq AQ
NLS Pharmaceutics - Notice of Deficiency with Nasdaq Continued Listing Requirements AQ
More press releases

News in other languages on NLS Pharmaceutics Ltd.

NLS Pharmaceutics Ltd.: NLS Pharmaceutics gibt neue In-vitro-Daten bekannt, die einzigartigen dualen Wirkmechanismus von Quilience(R) (Mazindol ER) bestätigen, einschließlich signifikanter Orexin-2-Rezeptor-Aktivität
NLS Pharmaceutics Ltd.: NLS Pharmaceutics lanciert F&E-Update-Webcast, um über das wachsende Portfolio unternehmenseigener präklinischer Wirkstoffe zu berichten
NLS Pharmaceutics Ltd.: NLS Pharmaceutics: Schreiben des CEO an die Aktionäre
NLS Pharmaceutics Ltd.: NLS Pharmaceutics gibt Abschluss von erster Tranche von Kaufabkommen mit BVF Partners LP in Höhe von 10,0 Mio. USD bekannt
NLS Pharmaceutics Ltd.: NLS Pharmaceutics sichert sich über Kaufvereinbarung mit BVF Partners L.P. einen Gesamtbruttoerlös von bis zu 30 Millionen Dollar
More news

Quotes and Performance

1 day-3.99%
1 week-6.02%
Current month-30.56%
1 month-30.56%
3 months-73.68%
6 months-77.68%
Current year-78.81%
More quotes

Highs and lows

1 week
0.11
Extreme 0.113
0.14
1 month
0.11
Extreme 0.113
0.19
Current year
0.11
Extreme 0.113
0.60
1 year
0.11
Extreme 0.113
1.53
3 years
0.11
Extreme 0.113
3.89
5 years
0.11
Extreme 0.113
7.35
10 years
0.11
Extreme 0.113
7.35
More quotes

Managers and Directors - NLS Pharmaceutics Ltd.

Managers TitleAgeSince
Eric Konofal FOU
 Founder 57 15-06-09
Alexander Zwyer FOU
 Founder 54 15-06-09
Elena Thyen-Pighin DFI
 Director of Finance/CFO - 23-05-19
Members of the board TitleAgeSince
Audrey Greenberg BRD
 Director/Board Member 51 23-06-29
Alexander Zwyer FOU
 Founder 54 15-06-09
Ronald Hafner FOU
 Founder 60 15-06-09
More insiders

Quotes

Date Price Change Volume
24-04-24 0.125 -3.99% 39,613
24-04-23 0.1302 +0.23% 325,436
24-04-22 0.1299 -2.11% 573,774
24-04-19 0.1327 0.00% 92,054
24-04-18 0.1327 -0.23% 96,906

Delayed Quote Nasdaq, April 24, 2024 at 04:00 pm EDT

More quotes

Company Profile

NLS Pharmaceutics AG, formerly NLS 1 Pharma AG, is a Switzerland-based company that operates as a biopharmaceutical company. The Company focuses on development of medicines for neurobehavioral and neurocognitive disorders treatment. The Company serves customers worldwide.
Sector
Biotechnology & Medical Research
More about the company

Income Statement Evolution

More financial data

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
NLS PHARMACEUTICS LTD. Stock NLS Pharmaceutics Ltd.
-78.81% 6.14M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+4.09% 43.43B
LONZA GROUP AG Stock Lonza Group AG
+47.81% 41.69B
MODERNA, INC. Stock Moderna, Inc.
+9.45% 41.31B
CELLTRION, INC. Stock Celltrion, Inc.
-10.92% 27.14B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+9.32% 25.28B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-24.87% 18.47B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.70% 12.59B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
+1.28% 12.33B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+7.78% 11.03B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. NLSP Stock